PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
85350709 |
LAW OFFICE ASSIGNED |
LAW OFFICE 116 |
MARK SECTION |
MARK |
BASAGLAR |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
BASAGLAR |
OWNER SECTION |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317-276-9624 |
FAX |
317-276-1919 |
EMAIL |
XXXX |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety
disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and
disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders,
hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle
diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders,
sleep disorders, urological disorders; antidepressants |
GOODS OR SERVICES DELETED FROM THE APPLICATION |
diagnosis and |
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders,
atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders,
cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal
diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases
and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep
disorders, urological disorders; antidepressants |
EXTENSION SECTION |
EXTENSION NUMBER |
4 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
12/27/2011 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
SIGNATURE |
/blongbottom/ |
SIGNATORY'S NAME |
Bruce W. Longbottom |
SIGNATORY'S POSITION |
Assistant General Counsel |
DATE SIGNED |
11/19/2013 |
SIGNATORY'S PHONE NUMBER |
317 651 1346 |
FILING INFORMATION |
SUBMIT DATE |
Tue Nov 19 14:34:21 EST 2013 |
TEAS STAMP |
USPTO/ESU-XX.X.XX.XX-2013
1119143421664397-85350709
-5005a56314cf2edb2a631419
a68e1ade3da0e17e2b8b33422
79a573af9823a399-DA-892-2
0131118192240071764 |
PTO Form 1581 (Rev 9/2005) |
OMB No. 0651-0054 (Exp. 10/31/2017) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: BASAGLAR
SERIAL NUMBER: 85350709
The applicant, Eli Lilly and Company, having an address of
Lilly Corporate Center
Indianapolis, Indiana 46285
United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 12/27/2011.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis,
autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders,
cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders,
inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders,
urological disorders; antidepressants
This filing does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are
permanently deleted from this application: diagnosis and
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and
disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia,
dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and
inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative
diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders;
antidepressants
This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false
statements may jeopardize the validity of the form or any resulting registration, declares that he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the
applicant to be the owner of the trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on information and belief
are believed to be true.
Signature: /blongbottom/ Date Signed: 11/19/2013
Signatory's Name: Bruce W. Longbottom
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317 651 1346
RAM Sale Number: 85350709
RAM Accounting Date: 11/20/2013
Serial Number: 85350709
Internet Transmission Date: Tue Nov 19 14:34:21 EST 2013
TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2013111914342166439
7-85350709-5005a56314cf2edb2a631419a68e1
ade3da0e17e2b8b3342279a573af9823a399-DA-
892-20131118192240071764